SummaryThe approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either hemophilia A or hemophilia B enrolled.
SummaryWith FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.